AI Optics’ Sentinel Camera gains FDA 510(k) clearance

News
Article

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

AI Optics' portable Sentinel Camera Image credit: AI Optics

AI Optics' portable Sentinel Camera Image credit: AI Optics

AI Optics, an AI-focused medical device company, has received FDA 510(k) clearance for its Sentinel Camera, a handheld retinal imaging system.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye. According to the company, this eliminates the need for some patients to visit an eye specialist’s office. Additionally, the Sentinel Camera supports DICOM-compliant image formats, allowing integration with Electronic Health Record (EHR) systems.

"The fact that this device provides truly immediate results is a massive differentiator," Matthew Alpert, OD, president of TEC Eye Consortium, told AI Optics.2 "No busy clinician has the time to wait for results. On top of that, it introduces an incremental revenue stream, differentiates your practice, and improves HEDIS scores.”

Luke Moretti, co-founder and CEO of AI Optics, commented on the device and clearance in a press release from the company.

"Our vision with the Sentinel Camera is to eliminate barriers to retinal screening and ensure that every patient who needs screening has access," said Moretti "This FDA clearance not only validates our significant progress to breaking down screening barriers but also sets the stage for our future AI-powered screening solutions, which will integrate seamlessly with the Sentinel Camera to deliver unparalleled accessibility and efficiency in retinal disease detection."

In addition to the clearance, AI Optics is developing AI-based retinal screening software for future integration. The company aims to provide a comprehensive end-to-end solution for detecting retinal diseases such as diabetic retinopathy, glaucoma, and macular degeneration.

AI Optics is also collaborating with NYU Langone Health with the goal of advancing the accessibility and implementation of retinal screening technology. According to the company, this clearance “marks a pivotal step in this journey, enabling the integration of high-quality, portable imaging into diverse healthcare environments.”

References:
  1. AI Optics Receives FDA Clearance, Increasing Patient Access to Retinal Screening. Press Release. Published January 28, 2025. Accessed January 28, 2025.https://investors.apellis.com/news-releases/news-release-details/apellis-receives-approval-syfovrer-pegcetacoplan-australia
  2. AI-powered retinal screening for optometry practices. AI Optics. Accessed February 6, 2025. https://www.aioptics.ai/optometry

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.